Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23531Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Briasoulis, E. | en |
| dc.contributor.author | Tsokos, M. | en |
| dc.contributor.author | Fountzilas, G. | en |
| dc.contributor.author | Bafaloukos, D. | en |
| dc.contributor.author | Kosmidis, P. | en |
| dc.contributor.author | Samantas, E. | en |
| dc.contributor.author | Skarlos, D. | en |
| dc.contributor.author | Nicolaides, C. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:33:23Z | - |
| dc.date.available | 2015-11-24T19:33:23Z | - |
| dc.identifier.issn | 0250-7005 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23531 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adenocarcinoma/metabolism | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Carcinoma/metabolism | en |
| dc.subject | Carcinoma, Squamous Cell/metabolism | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Neoplasms, Unknown Primary/*metabolism/mortality | en |
| dc.subject | Proto-Oncogene Proteins c-bcl-2/*metabolism | en |
| dc.subject | Tumor Suppressor Protein p53/*metabolism | en |
| dc.title | Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/9677443 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1998 | - |
| heal.abstract | We have previously shown that metastatic carcinomas of unknown primary site overexpress several tumor markers as well as the products of the oncogenes c-myc, ras and c-erbB2. We analyzed the tissue expression of the protein products of the apoptosis modulation genes p53 and bcl-2 in 47 CUP cases. Formalin-fixed, paraffin embedded tumor specimens were stained with commercially available antibodies to p53 (DO7) and bcl-2 after antigen retrieval by the microwave method. Staining was evaluated by intensity (1+ to 3+), percentage of positive cells (1-100%), and the 'intensity times percentage' product defined as the immunoreactivity index with values ranging from 0 to 300. Immunoreactivity index values higher than 150 were considered to characterize protein over-expression. Expression of p53 was identified in 70.2% of tumors while 53% of them showed a high immunoreactivity index. Bcl-2 expression was detected in 65% of tumors and overexpressed in 40%. Overexpression of both proteins was detected in 20% of tumors. The detection of either protein was not associated with any of the major clinicopathological variables studied. Nevertheless, a trend towards a more favourable response to platin based chemotherapy was seen in the cases that showed a strong expression of both proteins, when analysed by immunoreactivity index and percentage of positive cells. We conclude that CUP overexpress at a high percentage the p53 and the bcl2 proteins. The observed weak association of strong expression of these proteins with response to platin-based chemotherapy deserves further evaluation in the CUP setting. | en |
| heal.journalName | Anticancer Res | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
